Mark C. Markowski
@MarkowskiGUOnc
Genitourinary Oncologist. Associate Professor. Director of GU Oncology in the National Capital Region. Johns Hopkins SKCCC. Views are my own
You might like
We’re proud to announce that @US_FDA has granted DeNovo authorization for ArteraAI Prostate, establishing it as the first and only AI-powered software authorized to prognosticate long-term outcomes in patients with localized prostate cancer: urologytimes.com/view/fda-grant…
Aggies win 8-2 over the Wildcats. Aggies improve to 1-0 and the Wildcats move to 0-1
Very cool - nice work.
Check out our new work exploring AR biology in advanced prostate cancer: tinyurl.com/2s39jh8b. We found that tumours expressing a specific AR variant (ARv567es) have a distinct transcriptomic profile and are resistant to androgen deprivation and bipolar androgen therapy
Phase 2 trial of single agent rucaparib without ADT in patients with mHSPC who harbor germline mutations in HRR genes. Clinical and objective responses observed. @MarkowskiGUOnc doi.org/10.1093/oncolo…
Cancer Statistics 2025 are out! #prostatecancer incidence still on the rise, mortality basically flat. Get screened so you can get treatment _when needed_. #pcsm acsjournals.onlinelibrary.wiley.com/doi/epdf/10.33…
Can’t wait to talk about prostate cancer with patients and their caregivers.
Johns Hopkins Kimmel Cancer Center invites you to learn helpful information for treatment advances for metastatic prostate cancer: bit.ly/3DIl0rC @hopkinskimmel
Congrats to Etan Aber from @nciccr_gmb who lead this effort. Preliminary but provocative retrospective data showing PSA responses with SGLT2 inhibitors in patients with prostate cancer in absence of ADT. onlinelibrary.wiley.com/doi/10.1002/pr…
Such a pleasure working with @eaonc and @ChrisSweens1. Multimodal AI prostate test by @arteraAI prognostic for OS in patients with mHSPC on CHAARTED trial. Hopeful AI will predict response to treatment as next step. sciencedirect.com/science/articl…
We would like to inform you that your post has been published on @Oncodaily. Thank you for sharing! oncodaily.com/blog/193154
Bigger kid. Bigger fish. Happy Thanksgiving 2024!
Your natural history study with PSMA PET imaging will be incredibly important. We did not find an association between PSADT and a positive PSMA PET. To me this suggests that novel imaging may not inform who needs treatment. PSADT still the gold standard.
Since #EMBARK data there is a need to define high risk #BCR #ProstateCancer Best data I have seen comes from @HopkinsMedicine team Risk of mets at 5 years is only 26% for #PSA DT 6-9 months. Significantly lower risk than DT 3-6 mos or DT under 3 mos ascopubs.org/doi/10.1200/JC…
Great exchange of ideas and hope to collaborate in the future!@AarmstrongDuke , @MarkowskiGUOnc . Thanks to our Colleagues for your expertise Program for the Multidisciplinary Management of Prostate Cancer held at the National Cancer Institute @incanMX
Just opened a new GU Med Onc position @fredhutch @UWMedicine join our dynamic cohesive team committed to exceptional care, innovative research, mentorship, teaching, DEI, community outreach! apply.interfolio.com/158802 @nicoleflemingmd @JessicaHawleyMD @HsiehLab @HutchPresident
The Vanderbilt GU Program is looking for new faculty members. Clinical investigators with an interest in translational investigator-initiated trials across GU malignancies are preferred. Message me /@alantanmd for more details! Come work with stellar faculty in an amazing city!
Our haiku about #prostatecancer and the #PCFRetreat24 with @PCFnews by @Freitas_PedroFS @SylvanBacaLab What do you think? 😊 @DrRanaMcKay @EAntonarakis @MarkowskiGUOnc @DrChoueiri @soulehoward1 @AndreaMiyahira @mishabeltran @JoshLangMD
Super excited to see this work from Sangeeta Ray and her group! pubmed.ncbi.nlm.nih.gov/39324008/ @nirmishsingla @cpavmd @michael_gorin @MarkowskiGUOnc @liljasolnes. #PSMA #molecularimaging #theranostics
Such an incredibly important ‘negative’ study. Well designed and executed. Excellent job, @DrChoueiri and team
The Vanderbilt University Ingram Cancer Center Genitourinary team is expanding. We are seeking a GU medical oncology clinical investigator to join our innovative team. Please message me or @brian_rini to inquire further. We will also be at #ESMO24
United States Trends
- 1. Bama 17.6K posts
- 2. Oklahoma 26.6K posts
- 3. #UFC322 31.2K posts
- 4. Ty Simpson 3,649 posts
- 5. Jeremiah Smith 1,439 posts
- 6. BOOMER SOONER 1,810 posts
- 7. Iowa 19.2K posts
- 8. Mateer 3,072 posts
- 9. Sabatini 1,296 posts
- 10. Brent Venables 1,113 posts
- 11. #RollTide 3,205 posts
- 12. Benn 39K posts
- 13. Jungkook 250K posts
- 14. South Carolina 33.7K posts
- 15. Heisman 10.7K posts
- 16. Kline 1,561 posts
- 17. DeBoer 1,379 posts
- 18. Arbuckle 1,048 posts
- 19. Talty 1,625 posts
- 20. Ryan Williams 1,717 posts
You might like
-
PCF Science
@PCF_Science -
Jonathan Rosenberg MD
@DrRosenbergMSK -
Nima Sharifi
@NimaSharifiMD -
Emmanuel Antonarakis
@EAntonarakis -
Rana McKay, MD, FASCO
@DrRanaMcKay -
Hans Hammers
@HHammersMD -
Charles Ryan
@charlesryanmd -
Ana Aparicio
@aaparicioMD -
Christopher Sweeney, MBBS
@ChrisSweens1 -
Andrea Miyahira
@AndreaMiyahira -
Howard Soule
@soulehoward1 -
Chris Barbieri
@Chris_Barbieri1 -
Misha Beltran
@mishabeltran -
Andrew Armstrong
@AarmstrongDuke -
Tanya Dorff
@TDorffOnc
Something went wrong.
Something went wrong.